A joint statement released following a meeting in Canberra on 15 September 2026, detailed continued cooperation across the life sciences ecosystem. Both nations recognise the importance of this sector for enhancing health, fostering innovation, attracting investment, and creating high-value jobs. They share world-class capabilities in health and medical research, clinical development, biotechnology innovation, advanced manufacturing, and commercialisation.
Since the inaugural Strategic Innovation Dialogue in London in April 2024, life sciences have been a key priority for bilateral innovation cooperation. Engagement has strengthened across government, research, and industry, identifying opportunities throughout the life sciences value chain, from research and clinical validation to regulation, commercialisation, investment, and market access.
Cooperation will advance in areas including clinical trials, genomics and precision medicine, biotechnology innovation, digital health, advanced therapies, regulatory excellence, and pathways to commercialisation. This aims to support more efficient development, stronger partnerships, and greater opportunities for innovative companies in both markets.
Specific commitments include collaboration between the Therapeutic Goods Administration (TGA) and the Medicines and Healthcare products Regulatory Agency (MHRA) on regulatory approaches, including through the Access Consortium. Austrade and the UK Department for Business, Innovation, Science and Trade (BIST) will promote bilateral trade, investment, and innovation. Organisations like AUScelerate, UK Catapult, AusBiotech, and the UK BioIndustry Association (BIA) are also supporting collaborations in areas such as cell and gene therapies and advanced molecular imaging.
Both countries recognise the value of connecting researchers, clinicians, regulators, investors, and industry to translate scientific discoveries into safe and effective products, services and treatments that benefit patients and support economic growth.




